Physician

Rahul Ravilla, M.D

According to 2025 Medicare claims, Rahul Ravilla, M.D (NPI: 1003171778) practices hematology/oncology in the Albany-Schenectady-Troy, NY market, with the plurality of this provider's patient population coming from Albany, NY. This provider's primary affiliated billing organization is NEW YORK ONCOLOGY HEMATOLOGY, P.C. (NPI: 1609863448; TIN: 141799724) and primary practice location at 12206-5104. Ravilla is affiliated with the Bassett Accountable Care Partners, LLC (ACO ID: A2612), participating under the MSSP model.

Ravilla's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 478 traditional Medicare patients, billed 95,375 HCPCS/CPT codes, and received $2,518,452 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,905 prescription claims across 268 beneficiaries totaling $9,770,630 in drug costs, led by Xtandi (Enzalutamide). 2020 DME data shows 12 claims. Open Payments data shows 123 records totaling $493,087. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $43,122 to $2,518,452. Similarly, Part D prescription costs have moved sharply higher in recent years, from $18,989 to $9,770,630. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	84	2,456	$43,122
2019	370	52,830	$1,217,153
2020	357	53,375	$1,458,909
2021	387	70,258	$1,643,702
2022	340	81,666	$2,107,357
2023	462	112,657	$2,754,230
2024	478	95,375	$2,518,452

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	59	541	$18,989
2016	55	159	$7,365
2017	29	88	$3,068
2018	32	66	$43,662
2019	117	633	$865,293
2020	111	746	$1,395,148
2021	138	1,419	$3,600,283
2022	170	1,844	$5,435,788
2023	230	2,448	$7,704,429
2024	268	2,905	$9,770,630

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	12	$165
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	252	606	$93
80053	Blood test, comprehensive group of blood chemicals	325	999	$10
36415	Insertion of needle into vein for collection of blood sample	304	928	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	326	1,007	$8
83735	Magnesium level	225	728	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	147	4,440	$2,002,351
Cabometyx	Cabozantinib S-Malate	75	2,235	$1,821,181
Erleada	Apalutamide	90	2,710	$1,241,718
Nubeqa	Darolutamide	86	2,578	$1,087,270
Inlyta	Axitinib	46	1,357	$926,491

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	69	$91,857	Exelixis Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	54	$401,230	AstraZeneca UK Limited
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Rahul Ravilla, M.D?

Tedicare shows public-source Medicare data for Rahul Ravilla, M.D (NPI 1003171778), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rahul Ravilla, M.D have ACO affiliation data?

Rahul Ravilla, M.D is shown with ACO affiliation data for Bassett Accountable Care Partners, LLC (MSSP, ACO ID A2612).

What billing organization is linked to Rahul Ravilla, M.D?

Rahul Ravilla, M.D is linked to NEW YORK ONCOLOGY HEMATOLOGY, P.C. (billing NPI 1609863448) in the available physician profile data.

Does Rahul Ravilla, M.D have Open Payments data?

Rahul Ravilla, M.D has 123 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.